Francisco Gómez-García and Juan Ruano contributed equally to this work.
To view enhanced content for this article go to https://doi.org/10.6084/m9.figshare.6021824.
The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases.
We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual.
Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic.
Bou-Dargham MJ, Khamis ZI, Cognetta AB, Sang QA. The role of interleukin1 in inflammatory and malignant human skin diseases and the rationale for targeting interleukin-1 alpha. Med Res Rev. 2017;37:180–216.
Weber A, Wasiliew P, Kracht M. Interleukin 1 (IL-1) pathway. Sci Signal. 2010;3:cm1.
Dinarello CH. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147. PubMed
Novartis Pharmaceuticals Corporation. Prescribing information for ILARIS (canakinumab). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125319s047lbl.pdf. Accessed 12 Feb 2018.
Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015;33:621–31. CrossRefPubMedCentralPubMed
Al-Almaie SM, Al-Baghli NA. Evidence based medicine: an overview. J Fam Community Med. 2003;10:17–24.
Moher D, Stewart L, Shekelle P. All in the family: systematic reviews, rapid reviews, scoping reviews, realist reviews, and more. Syst Rev. 2015;22(4):183.
The Joanna Briggs Institute. The Joanna Briggs Institute reviewer’s manual 2015. http://joannabriggs.org/assets/docs/sumari/Reviewers-Manual_Methodology-for-JBI-Scoping-Reviews_2015_v2.pdf. Accessed 29 Sept 2016.
- A Scoping Review Protocol to Explore the Use of Interleukin-1-Targeting Drugs for the Treatment of Dermatological Diseases: Indications, Mechanism of Action, Efficacy, and Safety
Juan L. Sanz-Cabanillas
José L. Hernández Romero
Antonio Velez Garcia-Nieto
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II